After hosting a chat with management at his firm’s Healthcare Conference, Piper Jaffray analyst Matt O’Brien says Tandem Diabetes remains highly confident in a year-end Control IQ approval. However, the “market pause” seen in Q3 has extended into Q4 as customers await the next generation pump, O’Brien tells investors in a research note. As a result, the company reiterated that it expects fiscal 2019 sales in the previously disclosed range of $358M-365M, the analyst adds. While not necessarily surprising, the lack of Q4 upside may be disappointing to investors, which is likely the reason shares are down today, says O’Brien. Nonetheless, the analyst still expects a full year of Control IQ impact in 2020, which gives him confidence that the company can deliver 20%-plus growth next year. He reiterates an Overweight rating on Tandem Diabetes with a $70 price target. The stock in afternoon trading is down 8%, or $5.31, to $63.08.